Cargando…

ADMA, SDMA and L-arginine may be Novel Targets in Pharmacotherapy for Complications due to Cardiopulmonary Bypass

BACKGROUND: In this study, the effects of olmesartan therapy on asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA), L-arginine and inducible nitric oxide synthase (iNOS) levels were investigated in patients undergoing cardiopulmonary bypass. METHODS: Patients were randomly allocat...

Descripción completa

Detalles Bibliográficos
Autores principales: Kahraman, Aydın, Mutlu, Emre, Aldağ, Mustafa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Society of Medical Biochemists of Serbia 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5471654/
https://www.ncbi.nlm.nih.gov/pubmed/28680344
http://dx.doi.org/10.1515/jomb-2016-0025
_version_ 1783243987777224704
author Kahraman, Aydın
Mutlu, Emre
Aldağ, Mustafa
author_facet Kahraman, Aydın
Mutlu, Emre
Aldağ, Mustafa
author_sort Kahraman, Aydın
collection PubMed
description BACKGROUND: In this study, the effects of olmesartan therapy on asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA), L-arginine and inducible nitric oxide synthase (iNOS) levels were investigated in patients undergoing cardiopulmonary bypass. METHODS: Patients were randomly allocated to two groups, control and olmesartan. Olmesartan was administered 30 mg once a day beginning from preoperative day 5 to postoperative day 28 and on operation day. Blood was drawn from all patients and ADMA, SDMA, L-arginine and iNOS levels were analyzed at six time points (T1: before anesthesia induction, T2: during cardiopulmonary bypass, T3: five min after the cross-clamp was removed, T4: after protamine infusion, T5: on postoperative day 3 and T6: on postoperative day 28). RESULTS: In the olmesartan treated group, iNOS levels exhibited significant decreases at T2, T3, T4, T5 and T6 time points compared with control group (p<0.001, p<0.05, p<0.001, p<0.01, p<0.05 respectively). ADMA levels were significantly lower in olmesartan treated group than in control group at T3, T4, T5 and T6 time points (p<0.05, p<0.05, p<0.05, p<0.01 respectively). SDMA levels at T2, T3 and T6 time points were higher in control group than olmesartan group. L-Arginine levels were significantly higher at T2 and T3 time points in olmesartan treated group than control group (p<0.001, p<0.01). CONCLUSIONS: It was concluded that administration of olmesartan reduced plasma ADMA, SDMA, iNOS levels and enhanced L-arginine level in CPB time and it could reduce potential postoperative complications through reducing oxidative stress and inflammatory response in the postoperative period after coronary bypass surgery.
format Online
Article
Text
id pubmed-5471654
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Society of Medical Biochemists of Serbia
record_format MEDLINE/PubMed
spelling pubmed-54716542017-07-05 ADMA, SDMA and L-arginine may be Novel Targets in Pharmacotherapy for Complications due to Cardiopulmonary Bypass Kahraman, Aydın Mutlu, Emre Aldağ, Mustafa J Med Biochem Original Paper BACKGROUND: In this study, the effects of olmesartan therapy on asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA), L-arginine and inducible nitric oxide synthase (iNOS) levels were investigated in patients undergoing cardiopulmonary bypass. METHODS: Patients were randomly allocated to two groups, control and olmesartan. Olmesartan was administered 30 mg once a day beginning from preoperative day 5 to postoperative day 28 and on operation day. Blood was drawn from all patients and ADMA, SDMA, L-arginine and iNOS levels were analyzed at six time points (T1: before anesthesia induction, T2: during cardiopulmonary bypass, T3: five min after the cross-clamp was removed, T4: after protamine infusion, T5: on postoperative day 3 and T6: on postoperative day 28). RESULTS: In the olmesartan treated group, iNOS levels exhibited significant decreases at T2, T3, T4, T5 and T6 time points compared with control group (p<0.001, p<0.05, p<0.001, p<0.01, p<0.05 respectively). ADMA levels were significantly lower in olmesartan treated group than in control group at T3, T4, T5 and T6 time points (p<0.05, p<0.05, p<0.05, p<0.01 respectively). SDMA levels at T2, T3 and T6 time points were higher in control group than olmesartan group. L-Arginine levels were significantly higher at T2 and T3 time points in olmesartan treated group than control group (p<0.001, p<0.01). CONCLUSIONS: It was concluded that administration of olmesartan reduced plasma ADMA, SDMA, iNOS levels and enhanced L-arginine level in CPB time and it could reduce potential postoperative complications through reducing oxidative stress and inflammatory response in the postoperative period after coronary bypass surgery. Society of Medical Biochemists of Serbia 2017-01-25 /pmc/articles/PMC5471654/ /pubmed/28680344 http://dx.doi.org/10.1515/jomb-2016-0025 Text en © 2017 Aydın Kahraman et al. http://creativecommons.org/licenses/by-nc-nd/3.0 This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
spellingShingle Original Paper
Kahraman, Aydın
Mutlu, Emre
Aldağ, Mustafa
ADMA, SDMA and L-arginine may be Novel Targets in Pharmacotherapy for Complications due to Cardiopulmonary Bypass
title ADMA, SDMA and L-arginine may be Novel Targets in Pharmacotherapy for Complications due to Cardiopulmonary Bypass
title_full ADMA, SDMA and L-arginine may be Novel Targets in Pharmacotherapy for Complications due to Cardiopulmonary Bypass
title_fullStr ADMA, SDMA and L-arginine may be Novel Targets in Pharmacotherapy for Complications due to Cardiopulmonary Bypass
title_full_unstemmed ADMA, SDMA and L-arginine may be Novel Targets in Pharmacotherapy for Complications due to Cardiopulmonary Bypass
title_short ADMA, SDMA and L-arginine may be Novel Targets in Pharmacotherapy for Complications due to Cardiopulmonary Bypass
title_sort adma, sdma and l-arginine may be novel targets in pharmacotherapy for complications due to cardiopulmonary bypass
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5471654/
https://www.ncbi.nlm.nih.gov/pubmed/28680344
http://dx.doi.org/10.1515/jomb-2016-0025
work_keys_str_mv AT kahramanaydın admasdmaandlargininemaybenoveltargetsinpharmacotherapyforcomplicationsduetocardiopulmonarybypass
AT mutluemre admasdmaandlargininemaybenoveltargetsinpharmacotherapyforcomplicationsduetocardiopulmonarybypass
AT aldagmustafa admasdmaandlargininemaybenoveltargetsinpharmacotherapyforcomplicationsduetocardiopulmonarybypass